Clinical Trials Logo

Chronic Lymphocytic Leukemia clinical trials

View clinical trials related to Chronic Lymphocytic Leukemia.

Filter by:

NCT ID: NCT03943342 Not yet recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well the combination of ibrutinib and venetoclax works in treating patients with chronic lymphocytic leukemia whose cancer has stopped responding to ibrutinib alone. Both ibrutinib and venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving ibrutinib and venetoclax together after development of ibrutinib resistance may work better than discontinuing ibrutinib and switching to other chemotherapy drugs.

NCT ID: NCT03939234 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Peptide Vaccination With IO103 and IO120 in Patients With Chronic Lymphocytic Leukemia.

Start date: April 26, 2019
Phase: Phase 2
Study type: Interventional

This study is investigating the efficacy of PD-L1(IO103) and PD-L2(IO120) peptides in untreated CLL patients with unmutated IGHV gene status.

NCT ID: NCT03913949 Not yet recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Start date: April 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic lymphocytic leukemia and non-hodgkin's lymphoma.

NCT ID: NCT03893682 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Start date: April 30, 2019
Phase: Phase 1
Study type: Interventional

This study is being done to evaluate the safety, tolerability and effectiveness of CG-806 for the treatment of patients with the condition of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being.

NCT ID: NCT03892044 Not yet recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Start date: June 30, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of duvelisib when given together with nivolumab in treating patients with Richter syndrome or transformed follicular lymphoma. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving duvelisib and nivolumab may work better in treating patients with Richter syndrome or transformed follicular lymphoma compared to giving duvelisib or nivolumab alone.

NCT ID: NCT03884998 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma

Start date: March 18, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies best dose and how well copanlisib when given together with nivolumab works in treating participants with Richter's transformation or transformed indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab may work better in treating participants with Richter's transformation or transformed non-Hodgkin's lymphoma.

NCT ID: NCT03881592 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness

GO-CLLEAR
Start date: November 1, 2018
Phase:
Study type: Observational [Patient Registry]

This study will be a secondary use of data, focusing on patients treated with combination therapy Obi-Clb, R-Clb or R-B, in a non-interventional, open label, national, multicenter setting. Retrospective analysis of data coming from registry database CLLEAR (www.leukemia-cell.org )that capture data on clinical and treatment practices in CLL. Data will be retrospectively analyzed.

NCT ID: NCT03870633 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma

Start date: March 15, 2019
Phase:
Study type: Observational

This trial studies financial difficulty in participants with chronic lymphocytic leukemia and multiple myeloma. Assessment of financial difficulty may help to better understand the financial impact of cancer and come up with ways to help participants avoid financial problems during treatment.

NCT ID: NCT03847727 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia

Start date: December 3, 2013
Phase:
Study type: Observational

CLL is an incurable disease with conventional chemotherapy. In the absence of TP53 disruption, a chemoimmunotherapy (CIT) regimen is recommended as front-line and second-line treatment in those patients who attained a long progression-free survival (PFS) with the previous regimen. Bendamustine and rituximab (BR) is one of the most widely adopted CIT regimens, including second-line treatment. Unfortunately, durations of remission following BR combination therapy tend to be short in patients with heavily pre-treated disease or who have already received rituximab. The incorporation of a maintenance following induction chemotherapy to overcome the shorter remission durations in this population is a reasonable option.

NCT ID: NCT03844048 Not yet recruiting - Cancer Clinical Trials

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Start date: April 15, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.